Kestra FY26 Revenue Jumps 59% to $95M, Guides FY27 at $137M; Refinances Debt with $200M Term Loan
KMTS sits 83% above its 52-week low of $13.25.
Summary
Kestra Medical Technologies reported FY26 revenue of $95.1 million, up 59% year-over-year, and guided FY27 revenue to $137 million. The company also disclosed a $200 million debt refinancing and ongoing material weaknesses in internal controls.
Key Events · Earnings and Guidance · KMTS
-
FY26 Revenue Surges 59%
Revenue reached $95.1 million, driven by a 58% increase in patients using the ASSURE WCD. Gross profit doubled to $48.9 million, with gross margin improving to 51.4% from 40.5%.
-
FY27 Revenue Guidance of $137M
Management guided for FY27 revenue of $137 million, implying ~44% growth and likely exceeding consensus estimates, signaling strong commercial traction.
-
$200M Debt Refinancing
On July 10, 2026, Kestra entered a new $200 million senior secured term loan with Pharmakon, drawing $75 million initially. Proceeds repaid the existing $45 million term loan, with the remainder for general corporate purposes. The new facility carries a lower interest rate (SOFR + 5.50% vs. prior SOFR + 7.25%) and extends maturity to 2031.
-
Material Weaknesses in Internal Controls
The 10-K discloses material weaknesses in financial reporting controls, including insufficient accounting and IT resources, inadequate segregation of duties, and IT general control deficiencies. Remediation efforts are ongoing but not yet complete.
Analysis · KMTS · Industrial Applications And Services
Kestra's annual report reveals strong commercial momentum with revenue nearly doubling, but widening losses and persistent material weaknesses in financial controls temper the outlook. The concurrent $200 million debt refinancing, disclosed as a subsequent event, replaces a smaller, higher-cost facility and provides growth capital, though it adds leverage. The FY27 revenue guide of $137 million, released alongside the 10-K, likely exceeds Street expectations and signals confidence in the ASSURE WCD's market share gains. However, the material weaknesses—spanning IT controls, segregation of duties, and financial reporting—remain a governance overhang that could undermine investor confidence if not remediated.
At the time of this filing, KMTS was trading at $24.22 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $13.25 to $30.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.